A diagnostic biochip for the comprehensive analysis of MLL translocations in acute leukemia

De novo Acute Myeloid Leukemia Associated with t(11;17)(q23;q25) and <i>MLL</i>-<i>SEPT9 </i>Rearrangement in an Elderly Patient: A Case Study and Review of the Literature

“…However, as shown in table 1, MLL - SEPT9 transcripts at the molecular level have been reported in 14 cases of AML and MDS to date [2,3,6,8,9,10,11,12,13,14], including the present patient. Although the data are limited, all cases with the MLL - SEPT9 rearrangement involved myeloid neoplasms (13 AML and 1 MDS) (table 1), suggesting that the MLL-SEPT9 fusion is predominantly associated with AML/MDS [8].…”

Molecular dissection of t(11;17) in acute myeloid leukemia reveals a variety of gene fusions with heterogeneous fusion transcripts and multiple splice variants

“…Thus far, only a few cases with MLL-MLLT6 (Prasad et al, 1994;Schoch et al, 2003;Maroc et al, 2004;Suzukawa et al, 2005) fusions have been described, which may in part be attributable to the rare occurrence of such cases but also to the former assumption that RARA is located proximal to MLLT6. Previously, 5 cases involving MLL and a breakpoint proximal to RARA, suggesting a novel MLL partner in this region, have been described (Reeves et al, 1994;Dube et al, 2003;Classen et al, 2005;Douet-Guilbert et al, 2005;Kang et al, 2005).…”

“…However, MLL-MLLT6 fusions seem to occur in both childhood and adult AML, but not infant leukemia. Regarding the MLL-SEPT fusions, MLL-SEPT9 occurs in de novo infant, childhood, and adult as well as therapy-related leukemias (Osaka et al, 1999;Taki et al, 1999;Yamamoto et al, 2002;Maroc et al, 2004). In contrast, the occurrence of a MLL-SEPT6 fusion seems to be restricted to infants and young children, thus probably defining a distinct subgroup of childhood leukemia (Borkhardt et al, 2001;Ono et al, 2002;Slater et al, 2002;Fu et al, 2003;Kim et al, 2003).…”

Diagnostics of Molecular Markers in Childhood Acute Leukaemia Using Biochips

“…They are included in the last version of Leukogen-biochip for the analysis of 13 translocations. Another diagnostic biochip has been described which allowed the analysis of about thirty different gene partners, but the sensitivity limit of the assay is significantly lower: 1 blast cell per 10 normal (Maroc et al, 2004). During 2006-2009 the bone marrow samples of patients with leukemia of age 0 to 18 treated in hematological clinics were received and tested using the biochip-based approach for the presence of translocations.…”